The top 10 pipeline blowups, setbacks and snafus for H1 2021
Once the pandemic hit, it was instantly clear that the industry was going to create an entire pipeline of vaccines and new drugs to fight back against Covid-19. In doing so, it also became instantly clear that we were going to get a crash course on just how bad things can go.
In the backdrop to some spectacular successes, we saw some of the biggest players in biopharma stumble, fall and in some cases never get back up again. You can find some of the most significant setbacks in the list below.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.